Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Around the turn of the century, microbiologists at Danisco USA Inc. had a problem: The bacteria they used to make yogurt and cheese were getting infected with viruses. Investigating more deeply, the ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Agreement with IRRI marks Pairwise's third CGIAR partnership, enabling the research institute to use Fulcrum® genome editing technology to develop higher-yielding, more nutritious rice varieties that ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

After resigning from her role as chief medical officer at CRISPR Therapeutics, Phuong Khanh Morrow, M.D., is taking on the role of head of the oncology therapeutic area unit at Takeda. Morrow ...

-Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex ...

SAN DIEGO--(BUSINESS WIRE)--On January 9 th 2023, CRISPR QC has announced that they have closed their Seed Round at $1.6M and appoints George Bonaros to Board of Directors to fuel commercial growth of ...